Cellectis (CLLS) Enterprise Value (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.77% |
| Dec 31, 2025 | 26.33% |
| Sep 30, 2025 | -42.94% |
| Jun 30, 2025 | 18.69% |
| Mar 31, 2025 | 6.38% |
| Dec 31, 2024 | -9.11% |
| Sep 30, 2024 | 8.41% |
| Jun 30, 2024 | -14.83% |
| Mar 31, 2024 | -18.32% |
| Dec 31, 2023 | -105.66% |
| Sep 30, 2023 | -16.38% |
| Jun 30, 2023 | 1.62% |
| Mar 31, 2023 | -1,121.05% |
| Dec 31, 2022 | 107.25% |
| Sep 30, 2022 | 26.78% |
| Jun 30, 2022 | -772.43% |
| Mar 31, 2022 | -213.46% |
| Dec 31, 2021 | 108.12% |
| Sep 30, 2021 | 16.98% |
| Jun 30, 2021 | -3,382.98% |
| Mar 31, 2021 | 102.82% |
| Dec 31, 2020 | 8.69% |
| Sep 30, 2020 | 24.64% |
| Jun 30, 2020 | -14.98% |
| Mar 31, 2020 | 11.61% |
| Dec 31, 2019 | -8.10% |
| Sep 30, 2019 | 21.64% |
| Jun 30, 2019 | 2.09% |
| Mar 31, 2019 | -2.05% |
| Dec 31, 2018 | 5.59% |
| Sep 30, 2018 | 3.29% |
| Jun 30, 2018 | -63.26% |
| Mar 31, 2018 | 5.81% |
| Dec 31, 2017 | -2.20% |
| Sep 30, 2017 | 4.72% |
| Jun 30, 2017 | -9.96% |
| Mar 31, 2017 | 7.76% |
| Dec 31, 2016 | -1.13% |
| Sep 30, 2016 | 35.30% |
| Jun 30, 2016 | -2.76% |
| Mar 31, 2016 | -28.24% |
| Dec 31, 2015 | -175.64% |
| Sep 30, 2015 | -0.56% |
| Jun 30, 2015 | 3.21% |
| Mar 31, 2015 | -1,062.19% |